Transitioning to Pegylated Interferon for the Treatment of Cutaneous T-Cell Lymphoma: Meeting the Challenge of Therapy Discontinuation and a Proposed Algorithm

Figure 1

Timeline outlining the first sequencing and production of interferon-α-2b in Zurich [9], the demonstration that interferon is effective for CTCL treatment [4], human recombinant interferon-α-2b production [10], pegylation of interferon [11], and the discontinuation timeline [12–14].